LifeStance Health Group (NASDAQ:LFST) CTO Vukasin Paunovich Sells 42,067 Shares

LifeStance Health Group, Inc. (NASDAQ:LFST) CTO Vukasin Paunovich sold 42,067 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $12.87, for a total value of $541,402.29. Following the transaction, the chief technology officer directly owned 205,379 shares in the company, valued at $2,643,227.73. The trade was a 17.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Vukasin Paunovich also recently made the following trade(s):

• On Monday, August 10th, Vukasin Paunovich sold 44,394 shares of LifeStance Health Group stock. The shares were sold at an average price of $10.85, for a total value of $481,674.90.

LifeStance Health Group Trading Down 0.8%

LFST stock opened at $12.73 on Friday. LifeStance Health Group, Inc. has a one year low of $4.77 and a one year high of $13.15. The stock has a market cap of $4.94 billion, a price-to-earnings ratio of 97.93 and a beta of 1.22. The company has a fifty day moving average price of $11.49 and a two-hundred day moving average price of $8.80. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.38 and a quick ratio of 1.38.

LifeStance Health Group (NASDAQ:LFST) last posted its earnings results on Thursday, August 6th. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.03 by $0.03. The company had revenue of $435.35 million during the quarter, compared to analysts’ expectations of $414.58 million. LifeStance Health Group had a net margin of 3.19% and a return on equity of 3.39%. LifeStance Health Group’s quarterly revenue was up 26.1% compared to the same quarter last year. During the same quarter last year, the company posted ($0.01) EPS. Equities analysts anticipate that LifeStance Health Group, Inc. will post 0.16 EPS for the current year.

Institutional Investors Weigh In On LifeStance Health Group

Several hedge funds and other institutional investors have recently modified their holdings of LFST. BlackRock Inc. bought a new position in shares of LifeStance Health Group in the second quarter valued at approximately $389,293,000. Silversmith Partners I GP LLC purchased a new position in LifeStance Health Group during the 4th quarter worth $100,842,000. Vanguard Group Inc. grew its stake in shares of LifeStance Health Group by 21.1% in the 4th quarter. Vanguard Group Inc. now owns 17,700,041 shares of the company’s stock worth $124,608,000 after acquiring an additional 3,086,506 shares in the last quarter. Wellington Management Group LLP purchased a new stake in shares of LifeStance Health Group in the second quarter valued at about $30,881,000. Finally, Jennison Associates LLC lifted its position in shares of LifeStance Health Group by 38.5% during the first quarter. Jennison Associates LLC now owns 10,228,801 shares of the company’s stock valued at $65,157,000 after purchasing an additional 2,843,388 shares in the last quarter. Institutional investors own 85.50% of the company’s stock.

Analyst Ratings Changes

LFST has been the topic of several recent research reports. Zacks Research cut shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. The Goldman Sachs Group began coverage on LifeStance Health Group in a research report on Friday, June 5th. They set a “neutral” rating and a $9.00 price target on the stock. BTIG Research lifted their price objective on LifeStance Health Group from $16.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday, August 19th. Weiss Ratings upgraded LifeStance Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 11th. Finally, Canaccord Genuity Group boosted their price target on LifeStance Health Group from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $12.38.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.